US-based molecular diagnostics firm Cepheid, along with FIND, has introduced a new portable molecular diagnostics system GeneXpert Omni that will help in patient diagnosis suspected of TB, HIV and Ebola.
Weighing about 1kg, the new 9-inch tall system will run high quality PCR-based cartridge tests similar to the firm’s existing family of GeneXpert Systems.
GeneXpert Omni is battery-operated, wireless and web-enabled, allowing true point-of-care testing for conditions, including tuberculosis, drug-resistant tuberculosis, HIV and Ebola, to be carried out at the patient’s location.
Cepheid chairman and CEO John Bishop said: "For too long, access to best-in-class molecular diagnostics has been limited by the complexity of the tests and the systems that run them."
FIND CEO Dr Catharina Boehme said: "The majority of people in the developing world still lack access to adequate tests for common diseases, and Cepheid’s GeneXpert Omni has the potential to be a breakthrough platform on the path to achieving universal diagnosis."
Cepheid is exhibiting the GeneXpert Omni at the American Association of Clinical Chemistry (AACC) meeting in Atlanta, Georgia, which is being held from 28 to 30 July 2015.
GeneXpert Omni is expected to available for customers outside the US in the first half of 2016. At or near launch, the available test menu is expected to comprise Xpert MTB Ultra, Xpert HIV-1 Qualitative, Xpert HIV-1 Viral Load, Xpert HCV Viral Load, and Xpert Ebola.
Cepheid, along with not-for-profit organizations, is expanding access to quality molecular diagnostics with Xpert MTB/RIF, a test that was backed by the World Health Organization in December 2010.
Image: Cepheid’s new portable molecular diagnostics system GeneXpert Omni. Photo: courtesy of Cepheid.